Read on for updates across the Research we Enable Postmortem Tissue (PMT) Core The Target ALS Postmortem Core has now ...

The Target ALS Global Natural History Study (GNHS) is entering a new phase of discovery. As the only international, ...

Invested in Biomarker Innovation ALS is a heterogeneous disease with distinct subpopulations of cases clustering together based on common underlying biology and with distinct differences in the ...

Predicting Phenoconversion in Carriers of ALS Pathogenic Variants People carrying mutations known to cause ALS make up at ...

Artificial intelligence and machine learning now enable the rapid virtual design and testing of thousands of new molecules and the simulation of their interactions with therapeutic targets. Leading ...

Today, we mourn the loss of Brooke Eby. Brooke was a powerhouse. Witty, clever, joyful, and direct. She was unwilling to be ...

Key information that you need to know about planning for life with ALS. When you’re diagnosed with ALS, there are some decisions that can be helpful to understand early. Most decisions can wait until ...

This content is password-protected. To view it, please enter the password below.

In observational studies, researchers collect data from study participants without intervening in their care. Clinical trials evaluate the safety and efficacy of a specific intervention, like a drug, ...

We’re here to equip you with the knowledge and resources needed to navigate an ALS diagnosis and approach life with this disease. This content is password-protected ...

ALS (amyotrophic lateral sclerosis) is a disease that moves differently for everyone, but no one should have to face it ...